CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 23 enrolled
Drug / intervention
Itacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03697408
NCT03697408Phase 2Active
CompareCT.gov

An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib In Combination With Everolimus In Subjects With Relapsed/Refractory Classical Hodgkin Lymphoma

University of Pennsylvania·interventional·Posted Oct 5, 2018·Updated Jun 23, 2026

In Brief

A Phase 2 clinical trial evaluating Itacitinib and Everolimus for Classical Hodgkin Lymphoma. Active but no longer recruiting, targeting 23 participants across 1 site.

Detailed Summary

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassical Hodgkin Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
201920202021202220232024202520262027
First PostedOct 5, 2018
Enrollment StartFeb 11, 2019
Primary CompletionMay 20, 2024
Study CompletionJun 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.7 years ago

Interventions

Itacitinibdrug

A JAK 1 selective small molecule inhibitor

Everolimusdrug

A mammalian target of rapamycin (mTOR) inhibitor